The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study
Valbenazine, a highly selective vesicular monoamine transporter 2 inhibitor, is approved for the treatment of tardive dyskinesia. This is the first report of long-term effects in adults with tardive dyskinesia. Participants with a DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or a moo...
Saved in:
Published in | The journal of clinical psychiatry Vol. 78; no. 9; p. 1344 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.11.2017
|
Online Access | Get more information |
Cover
Loading…
Abstract | Valbenazine, a highly selective vesicular monoamine transporter 2 inhibitor, is approved for the treatment of tardive dyskinesia. This is the first report of long-term effects in adults with tardive dyskinesia.
Participants with a DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or a mood disorder who completed the 6-week, double-blind, placebo-controlled period of KINECT 3 were eligible to enter the 42-week valbenazine extension (VE) period and subsequent 4-week washout period. The extension phase was conducted from December 16, 2014, to August 3, 2016. Participants who received placebo and entered the VE period were re-randomized 1:1 to valbenazine 80 or 40 mg while others continued valbenazine at the KINECT 3 dose. Safety assessments included treatment-emergent adverse events (TEAEs) and scales for suicidal ideation/behavior, treatment-emergent akathisia or parkinsonism, and psychiatric symptoms. Efficacy assessments included the Abnormal Involuntary Movement Scale (AIMS) and Clinical Global Impression of Change-Tardive Dyskinesia (CGI-TD).
198 participants entered the VE period, 124 (62.6%) completed treatment (week 48), and 121 (61.1%) completed the follow-up visit after washout (week 52). During the VE period, 69.2% of participants had ≥ 1 TEAE, 14.6% had a serious TEAE, and 15.7% discontinued due to a TEAE. During washout, 13.1% of participants experienced a TEAE. No apparent risk for suicidal ideation or behavior was found. Long-term valbenazine treatment did not appear to induce or worsen akathisia or parkinsonism. Participants generally remained psychiatrically stable during the study. AIMS and CGI-TD measures indicated sustained tardive dyskinesia improvement, with scores returning toward baseline after 4 weeks of valbenazine washout.
The long-term safety and tolerability of valbenazine were generally favorable, and maintenance of treatment effect was apparent with both doses during this long-term study.
ClinicalTrials.gov identifier: NCT02274558. |
---|---|
AbstractList | Valbenazine, a highly selective vesicular monoamine transporter 2 inhibitor, is approved for the treatment of tardive dyskinesia. This is the first report of long-term effects in adults with tardive dyskinesia.
Participants with a DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or a mood disorder who completed the 6-week, double-blind, placebo-controlled period of KINECT 3 were eligible to enter the 42-week valbenazine extension (VE) period and subsequent 4-week washout period. The extension phase was conducted from December 16, 2014, to August 3, 2016. Participants who received placebo and entered the VE period were re-randomized 1:1 to valbenazine 80 or 40 mg while others continued valbenazine at the KINECT 3 dose. Safety assessments included treatment-emergent adverse events (TEAEs) and scales for suicidal ideation/behavior, treatment-emergent akathisia or parkinsonism, and psychiatric symptoms. Efficacy assessments included the Abnormal Involuntary Movement Scale (AIMS) and Clinical Global Impression of Change-Tardive Dyskinesia (CGI-TD).
198 participants entered the VE period, 124 (62.6%) completed treatment (week 48), and 121 (61.1%) completed the follow-up visit after washout (week 52). During the VE period, 69.2% of participants had ≥ 1 TEAE, 14.6% had a serious TEAE, and 15.7% discontinued due to a TEAE. During washout, 13.1% of participants experienced a TEAE. No apparent risk for suicidal ideation or behavior was found. Long-term valbenazine treatment did not appear to induce or worsen akathisia or parkinsonism. Participants generally remained psychiatrically stable during the study. AIMS and CGI-TD measures indicated sustained tardive dyskinesia improvement, with scores returning toward baseline after 4 weeks of valbenazine washout.
The long-term safety and tolerability of valbenazine were generally favorable, and maintenance of treatment effect was apparent with both doses during this long-term study.
ClinicalTrials.gov identifier: NCT02274558. |
Author | Correll, Christoph U Burke, Joshua Comella, Cynthia L Factor, Stewart A Remington, Gary Liang, Grace S Jimenez, Roland O'Brien, Christopher F |
Author_xml | – sequence: 1 givenname: Stewart A surname: Factor fullname: Factor, Stewart A email: sfactor@emory.edu organization: Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA – sequence: 2 givenname: Gary surname: Remington fullname: Remington, Gary organization: Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada – sequence: 3 givenname: Cynthia L surname: Comella fullname: Comella, Cynthia L organization: Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA – sequence: 4 givenname: Christoph U surname: Correll fullname: Correll, Christoph U organization: Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, New York, New York, USA – sequence: 5 givenname: Joshua surname: Burke fullname: Burke, Joshua organization: Neurocrine Biosciences, Inc, San Diego, California, USA – sequence: 6 givenname: Roland surname: Jimenez fullname: Jimenez, Roland organization: Neurocrine Biosciences, Inc, San Diego, California, USA – sequence: 7 givenname: Grace S surname: Liang fullname: Liang, Grace S organization: Neurocrine Biosciences, Inc, San Diego, California, USA – sequence: 8 givenname: Christopher F surname: O'Brien fullname: O'Brien, Christopher F organization: Neurocrine Biosciences, Inc, San Diego, California, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29141124$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j01LAzEYhIMo9kNvniV_YGs-N1lvsm61WrToKngq2ey7NNqmZZOq9de7UD3NwMw8MAN06NceEDqjZCSI1hd3-WxE1YpSpdQB6lMpZcIooT00COGdEJIqwo9Rj2VUUMpEH7XlAnDRNGBjwOsGv5plBd78OA_YeTwzbXTWbYzv4i8XF7g0be0-AV_vwkdXCs5c4icI2-V-HzscTd7AtPh-8lDkJea4-I7gg1t7_By39e4EHTVmGeD0T4foZVyU-W0yfbyZ5FfTxDKhY2Ig00LUGWeCSEuZlFRznXUnVOeshopUtgHgsmJWQpamtco0N1xqKjhL2RCd77mbbbWCer5p3cq0u_n_efYL7gtZtw |
ContentType | Journal Article |
Copyright | Copyright 2017 Physicians Postgraduate Press, Inc. |
Copyright_xml | – notice: Copyright 2017 Physicians Postgraduate Press, Inc. |
DBID | NPM |
DOI | 10.4088/JCP.17m11777 |
DatabaseName | PubMed |
DatabaseTitle | PubMed |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1555-2101 |
ExternalDocumentID | 29141124 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .55 .GJ 0R~ 1VV 1X7 3O- 53G 5GY 5RE 85S AAIKC AAMNW AAQQT AAUPJ AAWTO ABCQX ABIVO ABJNI ABPPZ ACALU ACBNA ACGFO ACGFS ACHQT ACNCT ADCOW AENEX AFFNX AFOSN AI. AIZTS ALMA_UNASSIGNED_HOLDINGS EBS EJD F5P FA8 HZ~ H~9 J5H L7B NEJ NPM O9- OHT P0W P2P PQQKQ SJN UHB VH1 WH7 X7M ZCA ZGI ZXP |
ID | FETCH-LOGICAL-c248t-ae9844d932405c1255183890007518c8eb0bcfee35b2c5e966d7983a358143262 |
IngestDate | Wed Oct 16 00:49:44 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
License | Copyright 2017 Physicians Postgraduate Press, Inc. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c248t-ae9844d932405c1255183890007518c8eb0bcfee35b2c5e966d7983a358143262 |
PMID | 29141124 |
ParticipantIDs | pubmed_primary_29141124 |
PublicationCentury | 2000 |
PublicationDate | 2017-11-01 |
PublicationDateYYYYMMDD | 2017-11-01 |
PublicationDate_xml | – month: 11 year: 2017 text: 2017-11-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The journal of clinical psychiatry |
PublicationTitleAlternate | J Clin Psychiatry |
PublicationYear | 2017 |
SSID | ssj0006703 |
Score | 2.5273213 |
Snippet | Valbenazine, a highly selective vesicular monoamine transporter 2 inhibitor, is approved for the treatment of tardive dyskinesia. This is the first report of... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1344 |
Title | The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29141124 |
Volume | 78 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1dT9swFLUKk6a9INgXHwP5YW9VWBPbicPbVHUgNBBC7QRPyE4ciQ1C1RZt8KP4jbvXdhNTMY3tJari2rV8T699r4-PCfnYUyqt8NYA0avSiDOTRFpxGRUpl8JUMAFaseej4_RgxA_PxFmn8xCwlm5nere4f_Jcyf9YFd6BXfGU7D9YtmkUXsBnsC88wcLwfLaNBy0h45u60qa2etGYxjhRnjLdnGEbIhyQKXQ3_YF090vl-HDT2yvXAq5C4-gcxX0grB_0h13WHfyyJHf0K40U7ff29wPpieaU5WMKtdN6dJsDllb2EzrW5lBPUd5kzuLfV20dcFVIzbKp3Lt6Bg12v7Zlk4nfMWnkEbqjMIUB02LcpDCMd7tCRBB8xqFfzmSAvzxwsjFzkpGL3p-Dx8SLrfsnu3F2jbvRWfg1GNHxtUVCkscc1pn876ULWtzzoiWylEn0p8eYG_LzfgrO0x2twI58CruBktO-6kL4Ypcxw1Wy4uMP-tmBaY10TP2avDzyDIs3ZAI2pR5T9KaiAaboZU1DTFHEFPWYoi2m9qhHFNYHRFGHKOoQRRltEEUtot6S0ZfBsH8Q-Xs5oiLhchYpk0vOyxy1HEUBK2QB84LM7fIzloU0uqeLyhgmdFIIAwF1meWSKZTa4xAuJO_Icn1Tm3VCy8qoKteCpWXJBctUojQ3ZWx0yhXTbIO8d6N1MXbiKxfzcdz8Y8kWedWC7AN5UcG_3WzD0nGmd6zFfgMw326x |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Effects+of+Valbenazine+in+Participants+with+Tardive+Dyskinesia%3A+Results+of+the+1-Year+KINECT+3+Extension+Study&rft.jtitle=The+journal+of+clinical+psychiatry&rft.au=Factor%2C+Stewart+A&rft.au=Remington%2C+Gary&rft.au=Comella%2C+Cynthia+L&rft.au=Correll%2C+Christoph+U&rft.date=2017-11-01&rft.eissn=1555-2101&rft.volume=78&rft.issue=9&rft.spage=1344&rft_id=info:doi/10.4088%2FJCP.17m11777&rft_id=info%3Apmid%2F29141124&rft_id=info%3Apmid%2F29141124&rft.externalDocID=29141124 |